Overexpression of bcl-2 Protects Prostate Cancer Cells from Apoptosis in Vitro and Confers Resistance to Androgen Depletion in Vivo

Cancer Research

Volumn 55, Issue 19, 1995, Pages 4438-4445

  Raffo, Anthony J ^a   Perlman, Harris ^a   Chen, Min Wei ^a   Streitman, Jack S ^a   Buttyan, Ralph ^a   Day, Mark L ^b  

^a The New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; COMPLEMENTARY DNA; DNA FRAGMENT; MESSENGER RNA; NEOMYCIN; ONCOPROTEIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROTECTION; CONTROLLED STUDY; DEPLETION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; SERUM; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANIMAL; APOPTOSIS; CELL LINE, TRANSFORMED; HUMAN; MALE; MICE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029077281     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Korsmeyer, S. J. Bcl-2: an antidote to programmed cell death. Cancer Surv., 15: 105–118, 1992.
2. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1–6, 1994.
3. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am. J. Pathol., 143: 390–400, 1993.
4. Nunez, G., London, L., Hockenberry, D., Alexander, M., McKearn, J. P., and Korsmeyer, S. J. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hematopoietic cell lines. J. Immunol., 144: 3602–3610, 1990.
5. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer, S. J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67: 879–888, 1991.
6. Walton, W. I., Whysong, D., O'Conner, P. M., Hockenberry, D., and Korsmeyer, S. J. Constitutive expression of human Bcl-2 modulates nitrogen mustard and campoth-ecin-induced apoptosis. Cancer Res., 53: 1853–1861, 1993.
7. Caron-Leslie, L. A., Evals, R. B., and Cidlowski, J. A. Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S49 cells. FASEB J., 9: 639–645, 1994.
8. Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U., Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. The LNCaP cell line: a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res., 37: 115–132, 1980.
9. Horoszewicz, J. S., Leong, S., Kawinski, E., Karr, J., Rosenthal, H., Chu, T., Miranel, E., and Murphy, J. LNCaP model of prostatic carcinoma. Cancer Res., 43: 1809–1818, 1983.
10. Montgomery, B. T., Young, C.Y.-F., Bilhartz, D. L., Andrews, P. E., Prescott, J. L., Thompson, N. F., and Tindall, D. J. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21: 63–73, 1992.
11. Israeli, R. S., Powell, C. T., Corr, J. G., Fair, W. R., and Heston, W. D. W. Expression of the prostate-specific membrane antigen. Cancer Res., 54: 1807–1811, 1994.
12. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkman, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Rev. Commun., 173: 534–540, 1990.
13. Sonnenschein, C., Olea, N., Pasanen, E., and Soto, A. M. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res., 49: 3474–3481, 1989.
14. Hockenberry, D. M., Nunez, G., Milliman, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334–336, 1990.
15. Chomezynski, P., and Sacchi, N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal. Biochem., 162: 156–159, 1987.
16. Katz, A. E., Benson, M. C., Wise, G. J., Olsson, C. A., Bandyk, M. G., Sawczuk, I. S., Tomashefsky, P., and Buttyan, R. Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res., 49: 5889–5894, 1989.
17. Klobeck, H. G., Combriato, G., Schultz, P., Arbusow, V., and Fittler, F. Genomic sequence of human prostate specific antigen (PSA). Nucleic Acids Res., 17: 398, 1989.
18. Janek, P., Briand, P., and Hartman, N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res., 35: 3698–3704, 1975.
19. Day, M. L., Zhao, X., Wu, S., Swanson, P. E., and Humphrey, P. A. Phorbol ester-induced apoptosis is accompanied by NGF1-A and c-fos activation in androgen-sensitive prostate cancer cell. Cell Growth & Differ., 5: 735–741, 1994.
20. Sensibar, J. A., Sutkowski, D. M., Raffo, A. J., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., and Lee, C. Prevention of cell death induced by tumor necrosis factor a in LNCaP cells by overexpression of sulfated glycoprotein 2 (clusterin). Cancer Res., 55: 2431–2437, 1995.
21. Pretlow, T., Delmore, C., Dilley, G., Spadafora, C., and Pretlow, T. Transplantation of human prostatic carcinoma into nude mice in Matrigel. Cancer Res., 51: 3814–3817, 1991.
22. Gleave, M. E., Hsieh, J.-T., Wu, H.-C., von Eschenbach, A. C., and Chung, L. W. K. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598–1605, 1992.
23. Lim, D. J., Liu, X.-L., Sutkowski, D. M., Braun, E. J., Lee, C., and Kozlowski, J. M. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate, 22: 109–118, 1993.
24. Tsujimoto, Y., and Croce, C. Analysis of the structure, transcripts and protein product of bcl-2, the gene involved in human follicular lymphoma. Proc. Natl. Acad. Sci. USA, 83: 5214–5218, 1986.
25. Villuendas, R., Piris, M. A., Orradre, J. L., Mollejo, M., Rodriguez, R., and Morente, M. Different bcl-2 protein expression in high-grade B-cell lymphomas derived from lymph node or mucosa-associated lymphoid tissue. Am. J. Pathol., 139: 989–993, 1991.
26. Joensuu, H., Pylkkanen, L., and Toikkanen, S. Bcl-2 protein expression and long term survival in breast cancer. J. Pathol., 145: 1191–1198, 1994.
27. McDonnell, T. J., Toncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J.-T., Tu, S.-M., and Campbell, M. J. Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940–6944, 1992.
28. Buttyan, R., and Olsson, C. A. Androgen receptor assays in advanced prostate cancer. Urol. Clin. N. Am., 11: 311–317, 1984.
29. Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., and Barrack, E. R. Androgen receptor gene mutations in prostate cancer. Proc. Natl. Acad. Sci. USA, 89: 6319–6323, 1992.
30. Tilly, W. D., Lim-Tio, S. S., Horsfall, D. J., Aspinall, J. O., Marshall, V. R., and Skinner, J. M. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Res., 54: 4096–4102, 1994.
31. Ruizeveld de Winter, J. A., Jannssen, P. J., Sleddens, H. M., Verleiun-Mooijman, M. C., Trapman, J., Brinkmann, A. O., Santerse, A. B., Schroder, F. H., and van der Kwast, T. H. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol., 144: 735–746, 1994.
32. Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, J., and Oren, M. p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13: 1415–1423, 1993.
33. Berges, R. R., Furuya, Y., Remington, L., English, H. F., Jacks, T., and Isaacs, J. T. Cell proliferation, DNA repair and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910–8914, 1993.
34. Colombel, M., Radvanyi, F., Blanche, M., Abbou, C., Buttyan, R., Donehower, L. A., Chopin, D., and Thiery, J. P. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene, 10: 1269–1274, 1995.
35. Voeller, H. J., Sugars, L. Y., Pretlow, T., and Gelman, E. P. p53 mutations in human prostate cancer specimens. J. Urol., 151: 492–495, 1994.
36. Kallakury, B. V., Figge, J., Ross, J. S., Fisher, H. A., Figge, H. L., and Jennings, T. A. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. Hum. Pathol., 25: 92–97, 1994.
37. Navone, N. M., Troncoso, P., Piters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657–1669, 1993.
38. Bookstein, R. Tumor suppressor genes in prostatic oncogenesis. J. Cell Biochem., 19 (Suppl.): 217–223, 1994.
39. Kitada, S., Takayama, S., De Riel, K., Tanaka, S., and Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense mediated reduction of bcl-2 gene expression. Antisense Res. Dev., 4: 1790–1794, 1994.
40. Oltvai, Z., Milliman, C., and Korsmeyer, S. J. Bcl-2 heterdimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74:609–619, 1993.
41. Lundreg, R., Mandhal, N., Heim, S., Limon, J., Henrickson, H., and Mitelman, F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes & Cancer, 4: 16–24, 1992.
42. Miyashita, T., Krajewski, S., Krajewski, M., Want, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799–1805, 1994.